A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521632-12-00

Enrollment

124

Registered

2026-05-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on Factor Xa inhibitor treatment needing an urgent intervention associated with a high risk of bleeding

Proportion of participants with good or excellent haemostatic efficacy during the required procedure as determined by an independent blinded EAC.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Measure	Time frame
Proportion of participants with good or excellent haemostatic efficacy during the required procedure as determined by an independent blinded EAC.	—

None listed

Source: EU CTIS · Data processed: May 21, 2026